Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02311348
Other study ID # 150025
Secondary ID 15-DK-0025
Status Completed
Phase N/A
First received December 5, 2014
Last updated June 30, 2017
Start date November 20, 2014
Est. completion date December 21, 2016

Study information

Verified date December 21, 2016
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: In a liver biopsy, a small piece of liver is removed. A percutaneous liver biopsy (PLB) is done through a needle on the right side of your belly. In a transjugular liver biopsy (TLB), the right side of the neck is numbed and a straw-like tube is put in. The tube goes down to your liver and a piece of liver is removed. Researchers want to learn more about the pain people feel after each of these procedures.

Objectives: To compare whether there is more pain associated with the PLB versus TLB.

Eligibility: Adults 18 years or older enrolled in a separate protocol (91-DK-0214) for liver biopsy. They must be able to read, write, and speak English.

Design: Under the separate protocol (91-DK-0214), participants will be screened and have a liver biopsy.

Before the biopsy, participants will give their medical history. They will answer questions about past surgeries and how they feel about pain.

Participants will have a pain test with a device called a dolorimeter. They will sit up with their feet on the ground, and put their thumbs on a table. They will feel pressure on each thumb until it they say it is painful.

Before the biopsy and 2, 4, and 6 hours after the biopsy, they will answer pain questions.


Description:

Millions of Americans are diagnosed with some form of Hepatitis or other liver disease requiring treatment. Liver biopsies are frequently performed mainly to stage disease, aid in diagnosis and to guide treatment. As part of the assessment of Hepatitis patients, a liver biopsy is frequently part of the regimen. Liver biopsy procedures can be performed using one of two methods: percutaneous liver biopsy (PLB) or transjugular liver biopsy (TLB). Alknawy & Shiffman (2007) discuss approaches of percutaneous liver biopsy that included the percussion-palpation approach, image guided, ultrasound assisted, ultrasound guided and type of biopsy needle used. The method of liver biopsy selected will not be randomly assigned but will be determined by the hepatologist caring for the patient. Pain can be a complication following a liver biopsy requiring adequate pain management.

Despite an extensive review of previous studies, none were found that discussed the pain experiences of patients who have undergone PLB versus TLB. This study proposes to compare the amount of pain experienced by patients who have undergone PLB versus TLB. Thirty-two male and female patients age 18 years and older who meet study criteria will be invited to participate. The participants will be placed into either the PLB or TLB group with each group consisting of 16 male or 16 female participants. Prior to the biopsy and within the first 6 hours post procedure, at the 2, 4 and 6-hour time points, the patient will be asked to rate their pain on the Visual Analogue Scale (VAS) and on the Numeric Pain Scale (NPS). Additionally, the dolorimeter will be used pre liver biopsy along with the VAS and the NPS as standardized pain measurements.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date December 21, 2016
Est. primary completion date December 21, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility - INCLUSION CRITERIA:

Criteria for subject selection will include the following:

1. 18 years of age or older

2. able to read, write and speak English.

3. capable of providing informed consent

4. subjects undergoing an elective PLB or TLB.

5. baseline pain level will be assessed prior to the liver biopsy using both VAS and NPS.

6. an assessment of pain threshold using a medical device called a dolorimeter.

7. must be enrolled into the 91-DK-0214 protocol

EXCLUSION CRITERIA:

1. patients who are unable to give consent will be excluded from the study.

2. Patient report of a pain level of four or more pre liver biopsy

3. The patient must undergo a baseline pain assessment prior to the liver biopsy using the dolorimeter.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain comparison between 2 groups 0, 2, 4, & 6 hour
See also
  Status Clinical Trial Phase
Completed NCT02798861 - Controlled Attenuation Parameter (CAP) in Liver Allografts
Completed NCT01968395 - Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Phase 4
Completed NCT01437969 - Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
Recruiting NCT00155376 - Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Phase 4
Recruiting NCT00172705 - Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique N/A
Completed NCT04185454 - Estimation of Minimum Efficacy Daily Dose of Jarlsberg Cheese N/A
Completed NCT02506335 - Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease Early Phase 1
Completed NCT02520609 - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Completed NCT02306018 - Evaluation of a New Calibrated Pulse Wave Analysis Method(EV1000™/volumeView™) for Cardiac Output Monitoring in Adult Liver Transplantation N/A
Completed NCT01988753 - Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Completed NCT01970904 - Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients N/A
Terminated NCT00741117 - Conjugated Hyperbilirubinemia and Pulse Oximetry N/A
Enrolling by invitation NCT01483248 - Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis Phase 1/Phase 2
Completed NCT00245830 - Ischemic Preconditioning of Liver in Cadaver Donors N/A
Completed NCT00074386 - Kidney and Liver Transplantation in People With HIV N/A
Completed NCT02329821 - Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection N/A
Completed NCT01650181 - Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Phase 4
Completed NCT01303549 - Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients Phase 4
Completed NCT00799851 - A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices Phase 4
Completed NCT00058890 - Gabapentin to Treat Itch in Patients With Liver Disease Phase 3